Semax

Overview

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Semax is a synthetic seven-amino-acid peptide developed at the Russian Academy of Sciences in the 1990s. It is structurally a fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-7) sequence Met-Glu-His-Phe, with a C-terminal Pro-Gly-Pro motif tacked on. That tail is not just decorative — it makes the peptide significantly more resistant to peptidase degradation than the natural ACTH fragment, which extends its half-life and biological activity.

In Russia, Semax sits in the Vital and Essential Drugs List and is used clinically for ischemic stroke recovery, ADHD in children, optic-nerve disease, and post-surgical cognitive support. Outside Russia it is not an approved medication. In the US, EU, and UK it exists only as a research chemical or via specialty compounding channels, with no FDA, EMA, or MHRA approval. The Russian clinical literature is substantial; Western peer-reviewed replication is limited.

The defining practical fact about Semax is that it is delivered intranasally. Ingested, it performs poorly because the GI tract degrades most of it. Injected, it reaches plasma but has trouble crossing the blood-brain barrier in meaningful concentrations. Snorted or dropped onto the upper nasal cavity, it travels along the olfactory and trigeminal nerve pathways straight into the central nervous system, bypassing both the gut and the BBB.

How it works

Evidence tier: 2 — mechanism documented in published pharmacology literature.

Three threads explain Semax's reported effects:

• Direct CNS delivery via the nose-to-brain route. This is the foundation of everything else. Without intranasal administration, the rest of the mechanism doesn't get a chance to act because the molecule never reaches the brain in useful concentration.
• Neurotrophic factor induction. Once in CNS tissue, Semax induces expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), particularly in the hippocampus and prefrontal cortex. These are the same factors implicated in long-term memory formation, mood regulation, and recovery from neuronal injury.
• Neurotransmitter modulation. Semax appears to modulate dopaminergic and serotonergic signalling in ways that produce acute effects on attention, motivation, and stress tolerance. The mechanism here is less well-characterized than the BDNF/NGF pathway but reproducible across animal studies.

The pharmacokinetic profile is unusual: plasma half-life is short (15–25 minutes), but downstream gene-expression effects on BDNF and NGF persist for 24 hours or longer. This is why users describe both an acute "lift" within minutes of dosing and a longer-running cognitive effect that outlasts measurable plasma exposure.

What the evidence actually shows

Evidence tier: 2 — references summarized in the body; see Trial readouts section below for primary-source detail.

Honest summary: most efficacy evidence comes from one research tradition (Russian) and one delivery route (intranasal).

• Stroke recovery. Multiple Russian RCTs (Gusev, Skvortsova, and colleagues, 2005 onward) report reduced mortality and improved NIHSS recovery scores when Semax is administered at 300–1200 µg/day intranasally during the first ten days post-stroke. Sample sizes range from 50 to 200 patients per trial. These trials are not registered in ClinicalTrials.gov and have not been replicated by Western research groups. By Russian regulatory standards this is approval-grade evidence; by Western standards it sits closer to Tier 2.
• ADHD in children. Russian open-label and small randomized trials report improvements in attention and reading metrics at low intranasal doses. No Western replication.
• Acute cognitive effects in healthy adults. Smaller human studies at standard research doses (300–600 µg) show EEG changes consistent with increased attentional tone and measurable improvements on vigilance tasks within 30–90 minutes. Self-reported subjective effects are commonly described as a slight, focused alertness rather than a stimulant-like rush.
• Long-term cognitive support and neuroprotection. Animal models support claims around hippocampal BDNF induction and neuroprotection in models of cerebral ischemia. Human chronic-use outcome data does not exist in the published literature.

A reader should weight Russian-originated trials carefully — not dismiss them, but recognize that the publication standards, registration practices, and trial-design conventions differ from current Western expectations.

Reported benefits

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Across the published clinical record and aggregated user logs:

• Acute attention and focus improvements within 10–30 minutes of intranasal dosing at 300–600 µg.
• Reduced perceived stress and improved task-performance under load.
• Subjective mood lift and motivation boost (uncharacterized in trials but consistent in user reports).
• Faster recovery of neurological function after ischemic stroke (Russian clinical evidence).
• Reported attention and reading-comprehension improvements in pediatric ADHD (Russian clinical evidence).
• Long-term cognitive support hypotheses based on BDNF/NGF induction (animal evidence; human evidence absent).

The acute cognitive effect is the most consistently reported and the easiest to evaluate yourself. Long-term claims sit on weaker evidence.

Risks and reported side effects

Evidence tier: 3 — clinical case-series + animal-model adverse-event data; magnitude varies by molecule.

The reported safety profile in Russian clinical use over three decades is reasonable but the long-term and high-dose Western use experience is shallower.

Reported side effects from trials and protocol logs:

• Local nasal irritation, burning, or transient runny nose — common, dose-dependent.
• Mild headache — uncommon, usually mild.
• Sleep disruption when dosed in the afternoon or evening — common at higher doses.
• Anhedonia or emotional flatness at very high chronic doses — anecdotal, not characterized in trials.
• Theoretical interaction with monoaminergic drugs (MAOIs, strong serotonergic agents) — no documented cases but plausible mechanism.

Specific caveats:

• Pregnancy and lactation — no safety data. Avoid.
• Active nasal pathology — polyps, septal ulceration, recent sinus surgery — delivery will be poor and irritation worse. Consider an alternative route.
• Substituting for emergency or specialist care — Semax is not a replacement for evaluated stroke treatment, ADHD diagnostic workup, or psychiatric care.
• Vendor quality — research-chemical Semax has highly variable purity. A meaningful number of "Semax" samples sold online have been characterized as containing wrong amino acids, low actual peptide content, or excessive bacterial endotoxin. ISO 17025 lab testing is the minimum verification.

Long-term safety data beyond the standard 10-day Russian clinical course does not exist in any published record.

Practical considerations

Evidence tier: 5 — community-evolved dose-range guidance; not RCT-derived.

If you are considering Semax under clinician supervision:

• Form. Russian-market Semax is sold as a 0.1% or 1% nasal solution. Each drop of 0.1% delivers approximately 50 µg of peptide; each drop of 1% delivers approximately 500 µg. Research-chemical Semax is typically sold as lyophilized powder for reconstitution into a similar concentration.
• Technique. Standard nose-drop technique deposits the dose in the anterior nasal cavity, where it enters systemic circulation but mostly misses the olfactory pathway. Head-back technique with controlled drops aimed at the upper nasal cavity, or specialty intranasal atomizers, raise the central bioavailability fraction substantially. Technique is one of the under-discussed reasons reported effects vary.
• Dose. Common protocols range from 50 µg/day (low-dose maintenance) to 1200 µg/day in divided doses (Russian post-stroke). Most cognitive-use protocols sit at 300–600 µg in the morning.
• Timing. Morning dosing avoids sleep disruption. Afternoon dosing is often regretted.
• Cycling. Intermittent use (5 days on, 2 off, or every other day) is the cautious default. Long-term continuous use has no human safety data.
• Storage. Reconstituted Semax is unstable at room temperature for more than a few weeks; refrigeration is required. Lyophilized powder is stable at room temperature but should be protected from humidity.

Where to go from here

Evidence tier: 5 — editorial framing of the peptide-page entity context.

For technical detail on the nose-to-brain pharmacokinetics, see our supporting article on Semax nasal spray bioavailability. For the broader Cognitive pillar including Selank and other neuropeptides, see the goal-based hub. For per-state regulatory status, see the legal status guide.

If you are a neurologist, psychiatrist, or pharmacologist interested in becoming a Medical Reviewer for our Cognitive cluster content, see the Medical Review Process page.

Related on Peptide Story

• Cognitive pillar — Russian neuropeptide research
• Semax vs Adderall — comparison
• Intranasal neuropeptide delivery science

References

• Kaplan A.Y. et al. 2017. Semax, an analogue of ACTH(4-10), regulates BDNF and TrkB expression in rat hippocampus. Neurosci Lett.
• Gusev E.I., Skvortsova V.I., Miasoedov N.F. et al. 2005. Efficacy of semax in acute ischaemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova.